AIP
GMAB icon

Almanack Investment Partners’s Genmab GMAB Stock Holding History

Almanack Investment Partners’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-538
Closed -$17K – 571
2022
Q3 		$17K Buy
+538
New +$18.9K ﹤0.01% 397

Other funds holding GMAB

AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
1832 Asset Management
1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Almanack Investment Partners's GMAB Position: Q4 2022 in Review

Almanack Investment Partners sold out of Genmab (GMAB) in Q4 2022, closing a stake of 538 shares — an estimated $17K sold.

Almanack Investment Partners first reported a position in GMAB in Q3 2022 and held it in 1 quarter. The position peaked at $17K in Q3 2022. 237 funds tracked by Wall St. Rank hold GMAB as of Q4 2022.

  • Almanack Investment Partners reported no remaining Genmab position as of Q4 2022 after selling out during the quarter.
  • Almanack Investment Partners sold 538 Genmab shares in Q4 2022, an estimated $17K.
  • Almanack Investment Partners first reported a position in Genmab in Q3 2022 and held it in 1 quarter.
  • Almanack Investment Partners's Genmab position peaked at $17K in Q3 2022.
  • 237 funds tracked by Wall St. Rank held Genmab as of Q4 2022.

Based on Almanack Investment Partners's 13F filing for Q4 2022, filed 9 Feb 2023.